RESUMEN
Patients with acquired haemophilia A usually show widespread subcutaneous bleeding. We describe an 86-year-old man with acquired haemophilia A associated with prostate carcinoma, showing initial localised giant haematoma and subsequent widespread subcutaneous bleeding. A localised giant haematoma may present as a first and important sign of acquired haemophilia A.
Asunto(s)
Carcinoma/diagnóstico , Hematoma/etiología , Hemofilia A/complicaciones , Hemofilia A/tratamiento farmacológico , Neoplasias de la Próstata/diagnóstico , Púrpura/etiología , Anciano de 80 o más Años , Carcinoma/complicaciones , Hematoma/tratamiento farmacológico , Hemofilia A/diagnóstico , Humanos , Masculino , Neoplasias de la Próstata/complicaciones , Púrpura/tratamiento farmacológicoRESUMEN
Cases of malignant melanoma on thermal burn scars have occasionally been reported. We report a 78-year-old Japanese female with malignant melanoma on a thermal burn scar with an interval of more than 70 years. Our case reemphasizes the importance of regular examinations in persons with thermal burn scars.
RESUMEN
Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Enfermedad de Hashimoto/etiología , Anciano , Femenino , Enfermedad de Hashimoto/sangre , Enfermedad de Hashimoto/inmunología , Humanos , Masculino , Melanoma/secundario , Melanoma/terapia , Nivolumab , Glándula Tiroides/diagnóstico por imagen , Hormonas Tiroideas/sangre , UltrasonografíaRESUMEN
Recovery with milia may occur in bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). Scarring commonly occurs in MMP and EBA. Here, we report a 62-year-old man patient with BP, who was left with numerous milia during recovery. The patient had immunoglobulin (Ig)G autoantibodies to the recombinant protein of the BP180-NC16a domain and the soluble 120-kDa ectodomain of BP180 (linear IgA bullous dermatosis [LAD]-1). There are cases of BP with IgG autoantibodies to LAD-1 and/or the recombinant protein of BP180 C-terminal domain. Extensive milia formation during recovery may be associated with immunological predisposition and/or improper interaction between hemidesmosomes and the extracellular matrix components.
Asunto(s)
Penfigoide Ampolloso/patología , Piel/patología , Humanos , Masculino , Persona de Mediana Edad , Penfigoide Ampolloso/tratamiento farmacológicoAsunto(s)
Productos Biológicos/efectos adversos , Excipientes/efectos adversos , Polisorbatos/efectos adversos , Psoriasis/tratamiento farmacológico , Urticaria/inducido químicamente , Adulto , Productos Biológicos/administración & dosificación , Productos Biológicos/química , Excipientes/administración & dosificación , Femenino , Humanos , Polisorbatos/administración & dosificación , Pruebas Cutáneas , Urticaria/diagnósticoAsunto(s)
Penfigoide Ampolloso/diagnóstico , Pénfigo/patología , Piel/patología , Anciano de 80 o más Años , Biopsia , Progresión de la Enfermedad , Quimioterapia Combinada/métodos , Femenino , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Penfigoide Ampolloso/tratamiento farmacológico , Penfigoide Ampolloso/inmunología , Penfigoide Ampolloso/patología , Pénfigo/tratamiento farmacológico , Pénfigo/inmunología , Prednisolona/uso terapéutico , Piel/inmunología , Resultado del TratamientoAsunto(s)
Liquen Plano/etiología , Síndromes Paraneoplásicos/etiología , Pénfigo/etiología , Timoma/complicaciones , Neoplasias del Timo/complicaciones , Anciano , Biopsia , Humanos , Liquen Plano/diagnóstico , Liquen Plano/patología , Masculino , Boca/patología , Miastenia Gravis/diagnóstico , Miastenia Gravis/etiología , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/patología , Pénfigo/diagnóstico , Pénfigo/patología , Piel/patología , Timoma/diagnóstico , Neoplasias del Timo/diagnósticoAsunto(s)
Leishmania tropica/aislamiento & purificación , Leishmaniasis Cutánea/diagnóstico , Adulto , Biopsia , ADN Protozoario/aislamiento & purificación , Humanos , Israel , Leishmania tropica/genética , Leishmaniasis Cutánea/parasitología , Leishmaniasis Cutánea/patología , Masculino , Piel/parasitología , Piel/patología , Adulto JovenRESUMEN
Patients with hematologic malignancies are immunosuppressive and may develop cutaneous or invasive infections as a primary sign of immune suppression. Acute promyelocytic leukemia (acute myeloid leukemia M3) is caused by translocation of reciprocal chromosomal rearrangement t(15;17), which produces an oncogenic protein. We herein describe a 71-year-old man having cellulitis with leukocytopenia as a first sign of acute promyelocytic leukemia. Dermatologists and hematologists should keep in mind that patients with a hematologic malignancy, such as acute promyelocytic leukemia, can develop cellulitis with leukocytopenia.